NasdaqGM:ATAIPharmaceuticals
AtaiBeckley Weighs Late Stage Options After Milestones And US$300m Raise
AtaiBeckley (NasdaqGM: ATAI) completed key Phase 2b and open label studies for BPL-003 in treatment resistant depression with robust outcomes.
The company redomiciled to the US and was added to the NASDAQ Biotechnology Index, aligning its structure with a US investor base.
AtaiBeckley raised $300 million to fund late stage clinical programs and entered a new partnership with Beckley Psytech.
For investors tracking mental health therapeutics, AtaiBeckley now sits at an interesting junction,...